CLAIMS

What is claimed is:

1. The compound 2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoic acid, or a tautomer, salt, and/or solvate thereof.

2. The compound 2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoic acid, or a salt thereof.

3. The compound 2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoic acid.

4. A pharmaceutical composition comprising the compound of any of claims 1-3 and at least one pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, further comprising at least one additional antiviral and/or anticancer agent.

6. At least one compound of any of claims 1-3 for use in the treatment and/or prevention of a disease or disorder caused by EBNA1 activity, wherein the disease or disorder is at least one selected from the group consisting of cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

7. Use of at least one compound of any of claims 1-3 in the manufacture of a medicament for the treatment and/or prevention of a disease or disorder caused by EBNA1 activity, wherein the disease or disorder is at least one selected from the group consisting of cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

8. The use of claim 7, wherein the cancer is at least one selected from the group consisting of nasopharyngeal carcinoma, gastric carcinomas, non-hodgkin lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt’s lymphoma, reticuloendotheliosis, reticulosis, microglioma, diffuse large B-

cell lymphoma, extranodal T/NK lymphoma/angiocentric lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphatic tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B cell lymphoma, lymphoplasmactic lymphoma, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lyphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, leiomyosarcomas, X-linked lymphoproliferative disease, post-transplant lymphoproliferative disorders, Hodgkin's lymphoma and breast cancer.

9. At least one compound of any of claims 1-3 for use in the treatment and/or prevention of Epstein-Barr Virus (EBV) infection, and/or a disease or disorder associated with EBV infection.

10. Use of at least one compound of any of claims 1-3 in the manufacture of a medicament for the treatment and/or prevention of Epstein-Barr Virus (EBV) infection, and/or a disease or disorder associated with EBV infection.

11. At least one compound of any of claims 1-3 for use in the treatment and/or prevention of lytic and/or latent EBV Virus infection.

12. Use of at least one compound of any of claims 1-3 in the manufacture of a medicament for the treatment and/or prevention of lytic and/or latent EBV Virus infection.

13. The use of any of claims 7-12, wherein the compound is to be administered by at least one route selected from the group consisting of oral, nasal, inhalational, topical, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratracheal, otic, intraocular, intrathecal, and intravenous routes.

14. The use of any of claims 7-13, wherein the compound is to be administered as part of a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier.